Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. (noting the metadata reference to Avalo Therapeutics appears to be an error, as the filing explicitly names Cerecor) on May 28, 2020. The report details the entry into a material definitive agreement and the receipt of regulatory clearance for a new clinical trial.
Key Financial Metrics and Agreements
The filing does not report standard financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it outlines the financial terms of a new partnership:
- Agreement: Amended and Restated Clinical Development and Option Agreement (New CDOA) with Kyowa Kirin Co., Ltd. (KKC).
- Initial License Fee: Low single-digit millions of dollars (payable upon exercise of the New Option).
- Regulatory Milestones: Up to an additional $14 million payable to KKC.
- Profit Split (ARDS/ALI Field): Cerecor retains approximately 75%; KKC receives approximately 25%.
- Royalties (Outside ARDS/ALI Field): KKC receives low double-digit royalties on sales.
Material Changes and New Developments
Two primary events constitute the material changes reported in this filing:
- Amendment of Prior Agreement: The New CDOA replaces a 2016 agreement. Key changes include the elimination of certain rights of first negotiation/refusal for Cerecor, an extension of KKC's time-based termination right, and the addition of a new option for the ARDS/ALI field.
- COVID-19 Clinical Trial Authorization: Cerecor received FDA clearance to proceed with a clinical trial of its antibody (CERC-002) for the treatment of COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).
Outlook, Risks, and Management Commentary
Outlook and Strategy: The company is pivoting to address the COVID-19 pandemic by conducting a signal-finding study for ARDS. If the New Option is exercised, Cerecor will be responsible for manufacturing and commercialization in the ARDS/ALI field globally.
Risks and Contingencies: The agreement contains customary early termination rights. The New CDOA will expire if neither the Original Option nor the New Option is exercised within their applicable periods. Certain terms of the agreement are subject to confidential treatment.
Investor Verification Checklist
- Verify the exact amount of the "low single-digit millions" initial license fee in the upcoming Form 10-Q.
- Confirm the specific regulatory milestones required to trigger the $14 million payment.
- Review the attached press release (Exhibit 99.1) for details on the design and timeline of the COVID-19 ARDS clinical trial.
- Monitor the upcoming Form 10-Q for the full text of the New CDOA and any redacted confidential terms.